It is active against estrogen-dependent breast tumors in postmenopausal women. Anastrozole is the main source of circulating estrogens in women in postmenopause, in peripheral tissues is converted to estron, and then to estradiol, this process takes place with the participation of the enzyme aromatase. The mechanism of action of anastrozole is related to inhibition of aromatase (selective non-steroidal inhibitor) in peripheral tissues, including fat, which leads to reduction of estradiol amount.
Adjuvant therapy of early hormone-positive breast cancer in postmenopausal women, treatment of common breast cancer in postmenopausal women, adjuvant therapy of early hormone-positive breast cancer in postmenopausal women after tamoxifen therapy for 2-3 years.
Preparations containing estrogens reduce the pharmacological effect of Anastrozole, so they should not be administered simultaneously with Anastrozole.
Tamoxifen should not be administered at the same time as Anastrozole because it can weaken the pharmacological effect of the latter. When Anastrozole and tamoxifen were used in patients with breast cancer, the plasma concentration of Anastrozole decreased by 27% compared to Anastrozole alone, and the combined administration did not affect the pharmacokinetics of tamoxifen and N-desmethyltamoxifen.